Anticonvulsant Profile of 4-Amino-(2-methyl-4-aminophenyl)benzamide in Mice and Rats
作者:Martial R. Kanyonyo、Jacques H. Poupaert、Didier M. Lambert
DOI:10.1111/j.1600-0773.1998.tb01397.x
日期:1998.1
Abstract: An original ameltolide analogue 4‐amino‐(2‐methyl‐4‐aminophcnyl)benzamide, in which a second amino group has been introduced, was synthesized and evaluated for anticonvulsant activity. After intraperitoneal administration to mice, 4‐amino‐(2‐methyl‐4‐aminophenyl)benzamide was found active in the maximal electroshock seizure test and against the tonic seizures elicited either by bicuculline or 3‐mercaptopropionic acid. 4‐amino‐(2‐methyl‐4‐arainophenyl)benzamidc (4A‐2M4A‐PB) gave anti maximal electroshock seizures ED50, of 63 umol/kg (15.4 mg/kg) and a TD50 of 676 μmol/kg (163 mg/kg), yielding a PI of 10.7: the potency is similar to that of the 4‐amino‐(2‐rnethyl‐3‐aminophenyl)phthalimide (4‐A‐2M3A‐PP), superior to that of 4‐amino‐(2,6‐dimethylphenyl)phlhaiimide (4A‐2,6‐DMPP), close to that of phenytoin and carbamazepine and inferior to that of ameltolide. 4A‐2M4A‐PB with an ED50 of 41 [28‐60] μmol/kg (9.9 mg/kg) is as active after oral administration to rats as carbamazepine, more active than ameltolide, 4‐A‐2M3A‐PP and phenytoin and slightly less active than the 4A‐2,6‐DMPP. The introduction of a second amino group on the substituted phenyl ring does not affect drastically the anticonvulsant potency after intraperitoneal administration to mice; moreover, it seems to enhance the activity after oral administration. 4A‐2M4A‐PB is a good candidate both for further pharmacokinetic studies and for the study of the precise mechanism of action.